Latest From Biotech Now

Release of BIO/Biomedtracker Drug Approval Rates Study

BIO and BioMedTracker are pleased to present the findings of their joint clinical trial success rates study.  Using clinical trial data from the past seven years, this analysis examines the most recent probability of success by treatment type, phase of development and therapeutic area. The overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2010 is near one in 10, not one in five to one Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

State of the Industry – From BIO Investor Forum 2010

Here is our slide deck from the 9th annual BIO Investor Forum in San Francisco: BIO Investor Forum 2010 final   From the media and blogosphere: Bloomberg in vivo blog Medical Technology Stock Letter

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

2010 BIO Business Forum Partnering Results

2010 BIO Business Forum in Chicago was a huge success last week. We hit record numbers for the three day event making this the single largest partnering event ever held. Our updated 1×1 partnering software system received over 107,000 requests for meetings that resulted in over 17,000 meetings. To put that in perspective, 10 years ago there were only 300 meetings, yielding an explosive 43% CAGR for partnering at the BIO International Convention.  The meetings were set up by some 2,100 Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Posts from the 12th Annual BIO CEO & Investor Conference in New York (Feb 2010)

I created a new page on the blog (now called the “CONFERENCES” tab) where key takeaways from conference panels, speakers, etc., can be posted. My first three are now up from the business panels at last week’s 12th Annual BIO CEO & Investor Conference in New York: NOTES FROM THE M&A PANEL NOTES FROM THE FINANCING PANELS NOTES FROM THE ‘GOING COMMERCIAL’ PANEL -David Thomas

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: ,

The booming H1N1 vaccine market

The vaccine market is booming – and biotech companies are just one of the beneficiaries.  A recent Associated Press Article explains that an increase in government support and newer, better technologies are just a part of it.  Patients look to benefit from new vaccinations on the horizon for diseases such as Alzheimer’s, herpes, malaria, and perhaps even a universal flu vaccine. It was just last month at the BIO Investor Forum’s H1N1 panel that panelists Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: , ,